Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) is expected to release its earnings data after the market closes on ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $34.94 which represents a slight increase of $0.89 or 2.61% from the prior close of $34.05. The stock opened at $33.85 and ...

Viking Therapeutics Inc.’s stock jumped 3% Tuesday, after a bullish note from Oppenheimer highlighted the company’s promising obesity-drug program and its potential appeal to a deep-pocketed ...

President Trump has issued more executive orders, aimed at the military, that range from the elimination of DEI policies to ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

First Solar will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on ...

In a recent transaction, J Matthew Singleton, a director at Viking Therapeutics, Inc. (NASDAQ:VKTX), sold 5,700 shares of the company's common stock. The transaction, which took... In a recent ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...